<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We tested the hypotheses that the glucagon response to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> is reduced in patients who are approaching the insulin-deficient end of the spectrum of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and that recent antecedent <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> shifts the glycemic thresholds for autonomic (including adrenomedullary <z:chebi fb="2" ids="28918">epinephrine</z:chebi>) and symptomatic responses to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> to lower plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Hyperinsulinemic stepped hypoglycemic clamps (85, 75, 65, 55, and 45 mg/dl steps) were performed on two consecutive days, with an additional 2 h of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> (50 mg/dl) in the afternoon of the first day, in 13 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>---7 treated with oral <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi> (OHA R(X); mean [+/- SD] HbA(1c) 8.6 +/- 1.1%) and 6 requiring therapy with insulin for an average of 5 years and with reduced C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels (insulin R(X), HbA(1c) 7.5 +/- 0.7%)---and 15 nondiabetic control subjects </plain></SENT>
<SENT sid="2" pm="."><plain>The glucagon response to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> was virtually absent (P = 0.0252) in the insulin-deficient type 2 diabetic patients (insulin R(X) mean [+/- SE] final values of 52 plus minus 16 vs. 93 plus minus 15 pg/ml in control subjects and 98 +/- 16 pg/ml in type 2 diabetic patients, OHA R(X) on day 1) </plain></SENT>
<SENT sid="3" pm="."><plain>Glucagon (P = 0.0015), <z:chebi fb="2" ids="28918">epinephrine</z:chebi> (P = 0.0002), and <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> (P = 0.0138) responses and neurogenic (P = 0.0149) and neuroglycopenic (P = 0.0015) symptom responses to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> were reduced on day 2 after <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> on day 1 in type 2 diabetic patients; these responses were not eliminated, but their glycemic thresholds were shifted to lower plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, the glycemic thresholds for these responses were at higher-than-<z:mpath ids='MPATH_458'>normal</z:mpath> plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations (P = 0.0082, 0.0028, 0.0023, and 0.0182, respectively) at baseline (day 1) in OHA R(X) type 2 diabetic patients, with relatively poorly controlled <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Because the glucagon response to falling plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels is virtually absent and the glycemic thresholds for autonomic and symptomatic responses to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> are shifted to lower <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations by recent antecedent <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, patients with advanced type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, like those with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, are at risk for <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>-associated <z:e sem="disease" ids="C0393911" disease_type="Disease or Syndrome" abbrv="">autonomic failure</z:e> and the resultant vicious cycle of recurrent iatrogenic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
</text></document>